InvestSMART

InhaleRx Limited (ASX:IRX)

ALERT: Price-sensitive ASX Announcement for IRX
Current share price for IRX : $0.028 0.003 (12%)+
Announcement
Release
10 Dec 2025 10:24AM
Price at Release
$0.025
Full Release
download
Summary
InhaleRx Limited, a clinical stage drug development company, is currently focused on developing three therapeutics to address significant unmet medical needs in pain management and mental health. The company's portfolio includes SRX-25, an oral esketamine and CYP-450 inhibitor targeting treatment-resistant depression (TRD), IRX-211 for breakthrough cancer pain (BTcP), and IRX-616a for panic disorder (PD). SRX-25 offers an alternative to existing esketamine therapies, aiming to improve adherence and convenience via a 505(b)(2) regulatory pathway. IRX-211 is in Phase 2 trials, with promising initial results and a strategic path for FDA and subsequent EMA and TGA approvals. IRX-616a is an innovative inhaled therapy for PD, with no current FDA-approved inhaled drugs in this space, addressing a market gap. All three programs are fully funded for their clinical development costs through an agreement with the Linlithgow Family Office, ensuring financial stability and progression towards potential market approvals.
Key Points
  • InhaleRx Limited is developing three drug candidates for unmet needs in pain management and mental health.
  • SRX-25 is an oral esketamine and CYP-450 inhibitor for treatment-resistant depression.
  • IRX-211 targets breakthrough cancer pain and is in Phase 2 trials with FDA approval pathways defined.
  • IRX-616a is an inhaled therapy for panic disorder with an opportunity due to lack of FDA-approved inhaled treatments.
  • All programs are fully funded through the Linlithgow Family Office agreement.
  • The company is rebranding to Nexalis Therapeutics to reflect its expanded drug portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.